Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Akbar Nawab

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
Research Square|May 18, 2026
A deformylase inhibitor expands therapeutic options for Lyme diseaseKim Lewis, Pankaj Patil, Hsin-Wen Liang, et al.
Frontiers in Oncology|August 2, 2021
Targeting Thymidylate Synthase Enhances the Chemosensitivity of Triple-Negative Breast Cancer Towards 5-FU-Based Combinatorial TherapyNair Hariprasad Haritha, Akbar Nawab, Vinod Vijayakurup, et al.
Frontiers in Oncology|January 1, 2024
Corrigendum: Targeting thymidylate synthase enhances the chemosensitivity of triple-negative breast cancer towards 5-FU-based combinatorial therapyNair Hariprasad Haritha, Akbar Nawab, Vinod Vijayakurup, et al.
JCI Insight|April 25, 2023
First-in-class multifunctional TYMS nonclassical antifolate inhibitor with potent in vivo activity that prolongs survivalMaria V Guijarro, Patrick C Kellish, Peter E Dib, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
Research Square|May 18, 2026
A deformylase inhibitor expands therapeutic options for Lyme diseaseKim Lewis, Pankaj Patil, Hsin-Wen Liang, et al.
Frontiers in Oncology|August 2, 2021
Targeting Thymidylate Synthase Enhances the Chemosensitivity of Triple-Negative Breast Cancer Towards 5-FU-Based Combinatorial TherapyNair Hariprasad Haritha, Akbar Nawab, Vinod Vijayakurup, et al.
Frontiers in Oncology|January 1, 2024
Corrigendum: Targeting thymidylate synthase enhances the chemosensitivity of triple-negative breast cancer towards 5-FU-based combinatorial therapyNair Hariprasad Haritha, Akbar Nawab, Vinod Vijayakurup, et al.
JCI Insight|April 25, 2023
First-in-class multifunctional TYMS nonclassical antifolate inhibitor with potent in vivo activity that prolongs survivalMaria V Guijarro, Patrick C Kellish, Peter E Dib, et al.
Pageof 4